Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report)'s stock price traded up 7.4% on Friday . The company traded as high as $21.75 and last traded at $21.75. 68,840 shares were traded during trading, an increase of 1% from the average session volume of 67,878 shares. The stock had previously closed at $20.26.
Wall Street Analyst Weigh In
Several research firms have issued reports on ORKA. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 19th. TD Cowen began coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a "buy" rating on the stock. Leerink Partnrs raised Oruka Therapeutics to a "strong-buy" rating in a report on Tuesday, September 17th. Leerink Partners began coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They issued an "outperform" rating and a $44.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday, November 25th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Oruka Therapeutics currently has an average rating of "Buy" and a consensus target price of $43.17.
View Our Latest Report on Oruka Therapeutics
Oruka Therapeutics Trading Up 7.3 %
The business's 50-day simple moving average is $25.60. The firm has a market cap of $760.55 million, a P/E ratio of -3.47 and a beta of 0.87.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC purchased a new position in Oruka Therapeutics in the third quarter valued at about $114,763,000. RTW Investments LP acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $45,359,000. Franklin Resources Inc. purchased a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $17,661,000. Braidwell LP purchased a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $12,640,000. Finally, Great Point Partners LLC acquired a new position in Oruka Therapeutics during the third quarter worth $12,614,000. Institutional investors and hedge funds own 56.44% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
